We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-2.52%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$439M
AUM Growth
+$75.3M
Cap. Flow
-$56.5M
Cap. Flow %
-12.86%
Top 10 Hldgs %
60.79%
Holding
73
New
15
Increased
16
Reduced
20
Closed
21

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$12M
2
JNJ icon
Johnson & Johnson
JNJ
+$11.1M
3
SIBN icon
SI-BONE Inc
SIBN
+$10.9M
4
ABBV icon
AbbVie
ABBV
+$10.8M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.29M

Top Sells

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$15M
2
LH icon
Labcorp
LH
+$12.9M
3
ICLR icon
Icon
ICLR
+$7.95M
4
HAE icon
Haemonetics
HAE
+$7.86M
5
CI icon
Cigna
CI
+$7.76M

Sector Composition

Rank Sector Weight
1 Healthcare 60.22%
2 Industrials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$73.8M 16.81%
+25,300
New +$11.2M
TRIL
2
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
$36.3M 8.27%
+206,800
New +$2.42M
ABBV icon
3
AbbVie
ABBV
$443B
$19.5M 4.43%
180,429
+94,915
+111% +$10.8M
HUM icon
4
Humana
HUM
$43.7B
$17.1M 3.9%
44,022
+28,231
+179% +$12M
JNJ icon
5
Johnson & Johnson
JNJ
$618B
$15.8M 3.61%
98,077
+65,079
+197% +$11.1M
HOLX
6
DELISTED
Hologic
HOLX
$14.8M 3.36%
200,119
+89,279
+81% +$6.7M
BIO icon
7
Bio-Rad Laboratories Class A
BIO
$8.71B
$13.6M 3.1%
18,272
+6,452
+55% +$4.83M
BMY icon
8
Bristol-Myers Squibb
BMY
$133B
$12.5M 2.85%
211,821
+110,740
+110% +$7.29M
ICLR icon
9
Icon
ICLR
$12.6B
$12.2M 2.79%
46,720
-32,695
-41% -$7.95M
THC icon
10
Tenet Healthcare
THC
$20.5B
$11.9M 2.71%
179,288
-38,603
-18% -$2.74M
SIBN icon
11
SI-BONE Inc
SIBN
$788M
$10.1M 2.3%
471,214
+431,059
+1,073% +$10.9M
SYNH
12
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$8.12M 1.85%
92,761
-37,477
-29% -$3.39M
VCYT icon
13
Veracyte
VCYT
$3.7B
$7.81M 1.78%
168,211
+28,000
+20% +$1.22M
CI icon
14
Cigna
CI
$73.7B
$7.24M 1.65%
36,188
-35,668
-50% -$7.76M
ELUT icon
15
Elutia
ELUT
$37.9M
$6.63M 1.51%
952,610
+79,451
+9% +$648K
AVTR icon
16
Avantor
AVTR
$9.32B
$6.62M 1.51%
161,963
+9,568
+6% +$374K
MCK icon
17
McKesson
MCK
$100B
$6.49M 1.48%
+32,551
New +$6.51M
ACH
18
Accendra Health
ACH
$237M
$6.38M 1.45%
203,784
+136,795
+204% +$5.38M
RCM
19
DELISTED
R1 RCM Inc. Common Stock
RCM
$6.23M 1.42%
282,911
-265,965
-48% -$5.5M
ATR icon
20
AptarGroup
ATR
$8.55B
$6.11M 1.39%
+51,191
New +$6.73M
OCUL icon
21
Ocular Therapeutix
OCUL
$1.79B
$6.1M 1.39%
610,401
+39,431
+7% +$443K
LH icon
22
Labcorp
LH
$25B
$5.3M 1.21%
21,917
-51,321
-70% -$12.9M
ADAP
23
DELISTED
Adaptimmune Therapeutics
ADAP
$4.74M 1.08%
917,488
-621,947
-40% -$2.79M
AHCO icon
24
AdaptHealth
AHCO
$1.47B
$4.54M 1.03%
+194,886
New +$4.71M
INSM icon
25
Insmed
INSM
$21.4B
$4.4M 1%
159,903
-100,411
-39% -$2.63M
1
2 3

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Endurant Capital Management held 73 positions worth $439M, up 21% from $364M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Endurant Capital Management withdrew a net $56.5M in Q3 2021, closing 21 positions and reducing 20 holdings. Its most notable exit was Thermo Fisher Scientific, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 80% a quarter earlier, followed by Industrials.

Against the trend, Endurant Capital Management opened a new position in AptarGroup worth $6.11M.

  • Endurant Capital Management's largest Q3 2021 buy was AptarGroup: 51,191 shares worth $6.11M.
  • Endurant Capital Management added most to Humana in Q3 2021, an estimated $12M increase.
  • Endurant Capital Management's biggest Q3 2021 reduction was Labcorp, cutting an estimated $12.9M.
  • Endurant Capital Management fully exited Thermo Fisher Scientific in Q3 2021, selling an estimated $15M.
  • Endurant Capital Management's ten largest holdings make up 61% of its $439M portfolio in Q3 2021.
  • Endurant Capital Management opened 15 new positions and closed 21 in Q3 2021.
  • Endurant Capital Management's portfolio value rose 21% quarter-over-quarter to $439M.

Based on Endurant Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.